3 Vaccine Maker, Metal Finishing Chemical and Footwear Stocks With a Strong Future Roadmap: GlaxoSmithKline Pharmaceuticals, Grauer & Weil (India) and Redtape

Vaccine maker, metal finishing chemical and footwear stocks give investors exposure to medicines, industrial chemicals and footwear used every day. Volumes, pricing and margins decide how much of that demand turns into profit.

This list covers three vaccine maker, metal finishing chemical and footwear stocks: GlaxoSmithKline Pharmaceuticals for branded medicines and vaccines sold through a large doctor network, Grauer & Weil (India) for surface treatment chemicals and related industrial products and Redtape for footwear, apparel and accessories sold through its own brand stores and online channels. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Vaccine Maker, Metal Finishing Chemical and Footwear Stocks?

Vaccine maker, metal finishing chemical and footwear stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Vaccine Maker, Metal Finishing Chemical and Footwear Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three vaccine maker, metal finishing chemical and footwear stocks as of the 14 Oct 2026 close.

Among healthcare, chemicals and consumer stocks, GSK Pharma trades at a premium to the industry P/E, while Grauer & Weil and Redtape trade at a discount.

Why Do Vaccine Maker, Metal Finishing Chemical and Footwear Stocks Have a Strong Roadmap in India?

Vaccine maker, metal finishing chemical and footwear stocks have a strong roadmap in India because vaccination demand, manufacturing output and branded footwear spending keep adding volumes for these firms. Three drivers stand out.

• Vaccination demand: Doctors prescribe more vaccines and branded medicines.
• Manufacturing output: Factories use surface treatment chemicals.
• Brand spending: Shoppers choose branded footwear and apparel.

GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap

GSK Pharma's roadmap rests on branded medicines and vaccines sold through a large doctor network, with established brands supporting steady sales.

Revenue grew from Rs 3,353.80 crore in FY22 to Rs 3,967.03 crore in FY26, an 18.3% rise, and FY26 revenue was 1.8% higher than FY25. FY26 net profit rose 11.7% to Rs 1,035.98 crore. Over four years, net profit rose from Rs 380.77 crore in FY22 to Rs 1,035.98 crore. In Q1 FY27, revenue grew 15.7% to Rs 982.20 crore, and net profit rose 15.7% to Rs 237.18 crore. Operating margin was 38.60% in FY26.

Debt to equity is 0.01 and return on equity is 45.69%. FY26 operating cash flow was Rs 903.30 crore against capital expenditure of Rs 55.28 crore. GSK Pharma paid a dividend of Rs 57 per share for FY26, a yield of 2.25%. At a P/E of 40.20 against an industry P/E of 37.59, the stock trades above its industry multiple.

What to watch: The P/E of 40.20 is a modest premium to the industry P/E of 37.59, so the next quarters' growth is the figure to follow.

Grauer & Weil (India): Surface Treatment Chemicals Drive the Pipeline

Grauer & Weil's roadmap rests on surface treatment chemicals and related industrial products, with several business lines supporting earnings.

Revenue grew from Rs 782.11 crore in FY22 to Rs 1,239.78 crore in FY26, a 58.5% rise, and FY26 revenue was 5.1% higher than FY25. FY26 net profit rose 4.3% to Rs 164.03 crore. Over four years, net profit rose from Rs 78.77 crore in FY22 to Rs 164.03 crore. In Q1 FY27, revenue grew 17.0% to Rs 311.11 crore. Operating margin was 18.87% in FY26.

Debt to equity is 0.01 and return on equity is 15.16%. FY26 operating cash flow was Rs 151.86 crore against capital expenditure of Rs 53.65 crore. Grauer & Weil paid a dividend of Rs 1 per share for FY26, a yield of 1.28%. At a P/E of 22.12 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: The P/E of 22.12 against an industry P/E of 36.60 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Redtape: A Footwear Brand Anchors the Roadmap

Redtape's roadmap rests on footwear, apparel and accessories sold through its own brand stores and online channels, with store expansion supporting growth.

FY26 revenue was Rs 2,551.61 crore, 17.5% higher than FY25. FY26 net profit rose 41.5% to Rs 240.55 crore. In Q1 FY27, revenue grew 4.8% to Rs 496.42 crore, and net profit rose 15.2% to Rs 44.48 crore. Operating margin was 20.07% in FY26 and 20.50% in Q1 FY27 against 18.56% a year earlier.

Debt to equity is 0.70 and return on equity is 23.55%. FY26 operating cash flow was Rs 174.01 crore against capital expenditure of Rs 85.92 crore. Redtape paid a dividend of Rs 2 per share for FY26, a yield of 1.76%. At a P/E of 25.49 against an industry P/E of 66.59, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 20.50% against 20.07% for FY26, so margin stability is the figure to follow as volumes grow.

Best Vaccine Maker, Metal Finishing Chemical and Footwear Stocks in India: GSK Pharma vs Grauer & Weil vs Redtape on Key Financials

Among the best vaccine maker, metal finishing chemical and footwear stocks in India, GSK Pharma leads on FY26 operating margin and return on equity; Grauer & Weil leads on Q1 FY27 revenue growth and the lowest P/E; Redtape leads on FY26 revenue growth and FY26 net profit growth. The table puts the numbers side by side.

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Vaccine Maker, Metal Finishing Chemical and Footwear Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen vaccine maker, metal finishing chemical and footwear stocks and shortlist vaccine maker, metal finishing chemical and footwear stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check revenue growth, operating margin and cash flow together.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these vaccine maker, metal finishing chemical and footwear stocks

Risks to Consider Before Investing in Vaccine Maker, Metal Finishing Chemical and Footwear Stocks

• Consumer demand: Spending patterns can shift sales between quarters.
• Input costs: Changes in raw material prices can affect margins.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track GSK Pharma, Grauer & Weil and Redtape live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover medicines, surface chemicals and footwear. GSK Pharma leads on FY26 operating margin and return on equity; Grauer & Weil leads on Q1 FY27 revenue growth and the lowest P/E; Redtape leads on FY26 revenue growth and FY26 net profit growth.

Across vaccine maker, metal finishing chemical and footwear stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the vaccine maker, metal finishing chemical and footwear stocks to buy discussed here.

FAQs on Vaccine Maker, Metal Finishing Chemical and Footwear Stocks

Which are the best vaccine maker, metal finishing chemical and footwear stocks in India with a strong roadmap?

Ans. GlaxoSmithKline Pharmaceuticals, Grauer & Weil (India) and Redtape stand out for their roadmaps in medicines, surface chemicals and footwear. FY26 revenue growth was 1.8% at GSK Pharma, 5.1% at Grauer & Weil and 17.5% at Redtape, and return on equity ranges from 15.16% to 45.69%.

Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?

Ans. GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 45.69% and a P/E of 40.20 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of GSK Pharma, Grauer & Weil and Redtape?

Ans. The P/E ratio is 40.20 for GSK Pharma (industry 37.59), 22.12 for Grauer & Weil (industry 36.60) and 25.49 for Redtape (industry 66.59). Only GSK Pharma trades at or above the industry multiple.

Which of these vaccine maker, metal finishing chemical and footwear stocks has the highest return on equity?

Ans. GlaxoSmithKline Pharmaceuticals has the highest return on equity at 45.69%, followed by Redtape at 23.55% and Grauer & Weil (India) at 15.16%.

What are the risks of investing in vaccine maker, metal finishing chemical and footwear stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did GSK Pharma, Grauer & Weil and Redtape perform in Q1 FY27?

Ans. GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore, up 15.7% year on year, and net profit rose 15.7% to Rs 237.18 crore. Grauer & Weil (India) reported revenue of Rs 311.11 crore, up 17.0% year on year. Redtape reported revenue of Rs 496.42 crore, up 4.8% year on year, and net profit rose 15.2% to Rs 44.48 crore.

Do vaccine maker, metal finishing chemical and footwear stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 2.25% for GSK Pharma, 1.28% for Grauer & Weil and 1.76% for Redtape, based on dividends declared for FY26.

How can I invest in vaccine maker, metal finishing chemical and footwear stocks in India?

Ans. You can buy vaccine maker, metal finishing chemical and footwear stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.